(Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-2) of higher dose 9 mg mazdutide (Innovent R&D Code: IBI362) , a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity
That decision should be made with your doctor based on your medical needs and risk factors, not legal considerations
Across early studies, GLP-1 drugs raised total testosterone in obese and diabetic men mostly by shrinking the fat tissue that converts testosterone into estrogen
It delivers 20 mg of biotin per serving, along with amino acids such as lysine and methionine, which are required for the production of structural proteins in hair and connective tissue
Insurance architecture, not clinical evidence, often determines who gets coverage
